Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-04-11

AUTHORS

Makoto Saito, Shuji Hatakeyama, Hideki Hashimoto, Takumitsu Suzuki, Daisuke Jubishi, Makoto Kaneko, Yukio Kume, Takehito Yamamoto, Hiroshi Suzuki, Hiroshi Yotsuyanagi

ABSTRACT

BackgroundDaptomycin has been reported to cause artificial prolongation of prothrombin time (PT) by interacting with some test reagents of PT. This prolongation was particularly prominent with high concentrations of daptomycin in vitro. However, whether this prolongation is important in clinical settings and the optimal timing to assess PT remain unclear.MethodsA prospective clinical study was conducted with patients who received daptomycin for confirmed or suspected drug-resistant, gram-positive bacterial infection at a university hospital in Japan. PT at the peak and trough of daptomycin was tested using nine PT reagents. Linear regression analyses were used to examine the difference in daptomycin concentration and the relative change of PT-international normalized ratios (PT-INR).ResultsThirty-five patients received daptomycin (6 mg/kg). The mean ± standard deviation of the trough and peak concentrations of daptomycin were 13.5 ± 6.3 and 55.1 ± 16.9 μg/mL, respectively. Twelve patients (34%) received warfarin. With five PT reagents, a significant proportion of participants experienced prolongation of PT-INR at the daptomycin peak concentration compared to the PT-INR at the trough, although the mean relative change was less than 10%. None of the participants clinically showed any signs of bleeding. A linear, dose-dependent prolongation of PT was observed for one reagent [unadjusted coefficient β 3.1 × 10−3/μg/mL; 95% confidence interval (CI) 2.3 × 10−5–6.3 × 10−3; p = 0.048]. When patients were stratified based on warfarin use, this significant linear relationship was observed in warfarin users for two PT reagents (adjusted coefficient β, 6.4 × 10−3/μg/mL; 95% CI 3.5 × 10−3–9.3 × 10−3; p < 0.001; and adjusted coefficient β, 8.3 × 10−3/μg/mL; 95% CI 4.4 × 10−3–1.2 × 10−2; p < 0.001). In non-warfarin users, this linear relationship was not observed for any PT reagents.ConclusionsWe found that a higher concentration of daptomycin could lead to artificial prolongation of PT-INR by interacting with some PT reagents. This change may not be clinically negligible, especially in warfarin users receiving a high dose of daptomycin. It may be better to measure PT at the trough rather than at the peak daptomycin concentration. More... »

PAGES

27

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12941-017-0203-3

DOI

http://dx.doi.org/10.1186/s12941-017-0203-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084746204

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28399872


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anti-Bacterial Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Anticoagulants", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bacterial Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Daptomycin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "False Positive Reactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hospitals, University", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indicators and Reagents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prothrombin Time", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Warfarin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Saito", 
        "givenName": "Makoto", 
        "id": "sg:person.0743612263.53", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743612263.53"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of General Internal Medicine, Division of Infectious Diseases, Jichi Medical University Hospital, 3311-1 Yakushiji, 329-0498, Shimotsuke-shi, Tochigi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.415016.7", 
          "name": [
            "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
            "Division of General Internal Medicine, Division of Infectious Diseases, Jichi Medical University Hospital, 3311-1 Yakushiji, 329-0498, Shimotsuke-shi, Tochigi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hatakeyama", 
        "givenName": "Shuji", 
        "id": "sg:person.0670630573.59", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670630573.59"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hashimoto", 
        "givenName": "Hideki", 
        "id": "sg:person.012505111435.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012505111435.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Takumitsu", 
        "id": "sg:person.07546217533.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07546217533.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jubishi", 
        "givenName": "Daisuke", 
        "id": "sg:person.010343600133.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010343600133.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kaneko", 
        "givenName": "Makoto", 
        "id": "sg:person.0765110307.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765110307.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kume", 
        "givenName": "Yukio", 
        "id": "sg:person.0676117053.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676117053.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Pharmacy, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yamamoto", 
        "givenName": "Takehito", 
        "id": "sg:person.01022254117.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022254117.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacy, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Pharmacy, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suzuki", 
        "givenName": "Hiroshi", 
        "id": "sg:person.012555337103.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012555337103.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.412708.8", 
          "name": [
            "Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yotsuyanagi", 
        "givenName": "Hiroshi", 
        "id": "sg:person.0623735761.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623735761.04"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1186/s12941-016-0130-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045323496", 
          "https://doi.org/10.1186/s12941-016-0130-8"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-04-11", 
    "datePublishedReg": "2017-04-11", 
    "description": "BackgroundDaptomycin has been reported to cause artificial prolongation of prothrombin time (PT) by interacting with some test reagents of PT. This prolongation was particularly prominent with high concentrations of daptomycin in vitro. However, whether this prolongation is important in clinical settings and the optimal timing to assess PT remain unclear.MethodsA prospective clinical study was conducted with patients who received daptomycin for confirmed or suspected drug-resistant, gram-positive bacterial infection at a university hospital in Japan. PT at the peak and trough of daptomycin was tested using nine PT reagents. Linear regression analyses were used to examine the difference in daptomycin concentration and the relative change of PT-international normalized ratios (PT-INR).ResultsThirty-five patients received daptomycin (6\u00a0mg/kg). The mean\u00a0\u00b1\u00a0standard deviation of the trough and peak concentrations of daptomycin were 13.5\u00a0\u00b1\u00a06.3 and 55.1\u00a0\u00b1\u00a016.9\u00a0\u03bcg/mL, respectively. Twelve patients (34%) received warfarin. With five PT reagents, a significant proportion of participants experienced prolongation of PT-INR at the daptomycin peak concentration compared to the PT-INR at the trough, although the mean relative change was less than 10%. None of the participants clinically showed any signs of bleeding. A linear, dose-dependent prolongation of PT was observed for one reagent [unadjusted coefficient \u03b2 3.1\u00a0\u00d7\u00a010\u22123/\u03bcg/mL; 95% confidence interval (CI) 2.3\u00a0\u00d7\u00a010\u22125\u20136.3\u00a0\u00d7\u00a010\u22123; p\u00a0=\u00a00.048]. When patients were stratified based on warfarin use, this significant linear relationship was observed in warfarin users for two PT reagents (adjusted coefficient \u03b2, 6.4\u00a0\u00d7\u00a010\u22123/\u03bcg/mL; 95% CI 3.5\u00a0\u00d7\u00a010\u22123\u20139.3\u00a0\u00d7\u00a010\u22123; p\u00a0<\u00a00.001; and adjusted coefficient \u03b2, 8.3\u00a0\u00d7\u00a010\u22123/\u03bcg/mL; 95% CI 4.4\u00a0\u00d7\u00a010\u22123\u20131.2\u00a0\u00d7\u00a010\u22122; p\u00a0<\u00a00.001). In non-warfarin users, this linear relationship was not observed for any PT reagents.ConclusionsWe found that a higher concentration of daptomycin could lead to artificial prolongation of PT-INR by interacting with some PT reagents. This change may not be clinically negligible, especially in warfarin users receiving a high dose of daptomycin. It may be better to measure PT at the trough rather than at the peak daptomycin concentration.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12941-017-0203-3", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.5908292", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1031269", 
        "issn": [
          "1476-0711"
        ], 
        "name": "Annals of Clinical Microbiology and Antimicrobials", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "prothrombin time", 
      "PT-INR", 
      "PT reagents", 
      "warfarin users", 
      "clinical studies", 
      "daptomycin concentrations", 
      "non-warfarin users", 
      "prospective clinical study", 
      "dose-dependent prolongation", 
      "artificial prolongation", 
      "positive bacterial infections", 
      "peak concentration", 
      "mean relative change", 
      "test reagents", 
      "vivo clinical studies", 
      "warfarin use", 
      "University Hospital", 
      "high dose", 
      "patients", 
      "linear regression analysis", 
      "bacterial infections", 
      "clinical setting", 
      "daptomycin", 
      "optimal timing", 
      "prolongation", 
      "regression analysis", 
      "warfarin", 
      "significant proportion", 
      "high concentrations", 
      "relative changes", 
      "significant linear relationship", 
      "participants", 
      "hospital", 
      "infection", 
      "dose", 
      "concentration", 
      "study", 
      "signs", 
      "ConclusionsWe", 
      "changes", 
      "proportion", 
      "setting", 
      "differences", 
      "relationship", 
      "time", 
      "timing", 
      "linear relationship", 
      "standard deviation", 
      "use", 
      "reagents", 
      "ratio", 
      "Japan", 
      "analysis", 
      "trough", 
      "interaction", 
      "peak", 
      "users", 
      "deviation"
    ], 
    "name": "Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study", 
    "pagination": "27", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084746204"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12941-017-0203-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28399872"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12941-017-0203-3", 
      "https://app.dimensions.ai/details/publication/pub.1084746204"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_739.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12941-017-0203-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12941-017-0203-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12941-017-0203-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12941-017-0203-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12941-017-0203-3'


 

This table displays all metadata directly associated to this object as RDF triples.

263 TRIPLES      21 PREDICATES      101 URIs      92 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12941-017-0203-3 schema:about N2533938454c4476fb74fa5b887edc842
2 N25bb09004ad541d693749bf103f17161
3 N3256b49af6fe4958a84490bc13febc93
4 N3877ebd006054cff981eb74eb451b2e8
5 N3b7ea7cebdf74ba79bc8f4a721f1d008
6 N3d8579f0a2ab4dcca10094b0cafca03a
7 N5faff8a7017f4ba0a27514bb917bd5c6
8 N9578607187a540df90256e6d1a6c68a1
9 N9bc50042f115409ab736bba9d970609a
10 Nb302cd924fea49b0a2e9094c18b8e6c9
11 Nc5691f2f525e4acb8520c35047f0b766
12 Ncf58b6c6388e4b839aae300325c78878
13 Nd7cf7de815194ee0a529b6e4cde51e3d
14 Nedfb11e27fe045ff9046ee6f6ad9fb73
15 Nef52197ad77141a3be6cdd27f14a7500
16 Nfb775fc9ef2c4cdd8aed4ad9af19adb5
17 Nfcfeb690913c44b9a79027b1199e3114
18 anzsrc-for:11
19 anzsrc-for:1117
20 schema:author Nd1f31491c33d4540bc3b097530bf22b0
21 schema:citation sg:pub.10.1186/s12941-016-0130-8
22 schema:datePublished 2017-04-11
23 schema:datePublishedReg 2017-04-11
24 schema:description BackgroundDaptomycin has been reported to cause artificial prolongation of prothrombin time (PT) by interacting with some test reagents of PT. This prolongation was particularly prominent with high concentrations of daptomycin in vitro. However, whether this prolongation is important in clinical settings and the optimal timing to assess PT remain unclear.MethodsA prospective clinical study was conducted with patients who received daptomycin for confirmed or suspected drug-resistant, gram-positive bacterial infection at a university hospital in Japan. PT at the peak and trough of daptomycin was tested using nine PT reagents. Linear regression analyses were used to examine the difference in daptomycin concentration and the relative change of PT-international normalized ratios (PT-INR).ResultsThirty-five patients received daptomycin (6 mg/kg). The mean ± standard deviation of the trough and peak concentrations of daptomycin were 13.5 ± 6.3 and 55.1 ± 16.9 μg/mL, respectively. Twelve patients (34%) received warfarin. With five PT reagents, a significant proportion of participants experienced prolongation of PT-INR at the daptomycin peak concentration compared to the PT-INR at the trough, although the mean relative change was less than 10%. None of the participants clinically showed any signs of bleeding. A linear, dose-dependent prolongation of PT was observed for one reagent [unadjusted coefficient β 3.1 × 10−3/μg/mL; 95% confidence interval (CI) 2.3 × 10−5–6.3 × 10−3; p = 0.048]. When patients were stratified based on warfarin use, this significant linear relationship was observed in warfarin users for two PT reagents (adjusted coefficient β, 6.4 × 10−3/μg/mL; 95% CI 3.5 × 10−3–9.3 × 10−3; p < 0.001; and adjusted coefficient β, 8.3 × 10−3/μg/mL; 95% CI 4.4 × 10−3–1.2 × 10−2; p < 0.001). In non-warfarin users, this linear relationship was not observed for any PT reagents.ConclusionsWe found that a higher concentration of daptomycin could lead to artificial prolongation of PT-INR by interacting with some PT reagents. This change may not be clinically negligible, especially in warfarin users receiving a high dose of daptomycin. It may be better to measure PT at the trough rather than at the peak daptomycin concentration.
25 schema:genre article
26 schema:isAccessibleForFree true
27 schema:isPartOf N29f543855fb847bab69f379e3f40740f
28 N588515087fc54352b9b9547eadfd7e1e
29 sg:journal.1031269
30 schema:keywords ConclusionsWe
31 Japan
32 PT reagents
33 PT-INR
34 University Hospital
35 analysis
36 artificial prolongation
37 bacterial infections
38 changes
39 clinical setting
40 clinical studies
41 concentration
42 daptomycin
43 daptomycin concentrations
44 deviation
45 differences
46 dose
47 dose-dependent prolongation
48 high concentrations
49 high dose
50 hospital
51 infection
52 interaction
53 linear regression analysis
54 linear relationship
55 mean relative change
56 non-warfarin users
57 optimal timing
58 participants
59 patients
60 peak
61 peak concentration
62 positive bacterial infections
63 prolongation
64 proportion
65 prospective clinical study
66 prothrombin time
67 ratio
68 reagents
69 regression analysis
70 relationship
71 relative changes
72 setting
73 significant linear relationship
74 significant proportion
75 signs
76 standard deviation
77 study
78 test reagents
79 time
80 timing
81 trough
82 use
83 users
84 vivo clinical studies
85 warfarin
86 warfarin use
87 warfarin users
88 schema:name Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study
89 schema:pagination 27
90 schema:productId N1a54c105dd3c4bf1ae9ccac5125a8880
91 Nb59ab587d2c747e292cd583f3809445a
92 Nd57852dbbcd549fa8ab514a6c2f7227a
93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084746204
94 https://doi.org/10.1186/s12941-017-0203-3
95 schema:sdDatePublished 2022-09-02T16:01
96 schema:sdLicense https://scigraph.springernature.com/explorer/license/
97 schema:sdPublisher Na9fa56151cf04b309421ca67eba07583
98 schema:url https://doi.org/10.1186/s12941-017-0203-3
99 sgo:license sg:explorer/license/
100 sgo:sdDataset articles
101 rdf:type schema:ScholarlyArticle
102 N18f8bef8b9a445dcb51a9b88561edd6b rdf:first sg:person.0670630573.59
103 rdf:rest N9adcf72d718a4aea9397deca770c4b6f
104 N1a54c105dd3c4bf1ae9ccac5125a8880 schema:name doi
105 schema:value 10.1186/s12941-017-0203-3
106 rdf:type schema:PropertyValue
107 N2533938454c4476fb74fa5b887edc842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Female
109 rdf:type schema:DefinedTerm
110 N25bb09004ad541d693749bf103f17161 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Aged
112 rdf:type schema:DefinedTerm
113 N29f543855fb847bab69f379e3f40740f schema:volumeNumber 16
114 rdf:type schema:PublicationVolume
115 N3256b49af6fe4958a84490bc13febc93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N3877ebd006054cff981eb74eb451b2e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Warfarin
120 rdf:type schema:DefinedTerm
121 N3b7ea7cebdf74ba79bc8f4a721f1d008 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Anti-Bacterial Agents
123 rdf:type schema:DefinedTerm
124 N3d8579f0a2ab4dcca10094b0cafca03a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Middle Aged
126 rdf:type schema:DefinedTerm
127 N50529ef8bde04f1ab256aae0db69d552 rdf:first sg:person.0765110307.99
128 rdf:rest Nc452c45ac90142c3915544b4e36ff06a
129 N588515087fc54352b9b9547eadfd7e1e schema:issueNumber 1
130 rdf:type schema:PublicationIssue
131 N5faff8a7017f4ba0a27514bb917bd5c6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name False Positive Reactions
133 rdf:type schema:DefinedTerm
134 N927e31f4dd474e92a8fd008455cff0ef rdf:first sg:person.012555337103.96
135 rdf:rest Nc82b2579b54e46f4a4e80832bad5d735
136 N94322bd6b773406aa5aad0265265deeb rdf:first sg:person.010343600133.61
137 rdf:rest N50529ef8bde04f1ab256aae0db69d552
138 N9578607187a540df90256e6d1a6c68a1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Hospitals, University
140 rdf:type schema:DefinedTerm
141 N974032c5a75441cea3bfad2d337b417e rdf:first sg:person.07546217533.04
142 rdf:rest N94322bd6b773406aa5aad0265265deeb
143 N9adcf72d718a4aea9397deca770c4b6f rdf:first sg:person.012505111435.41
144 rdf:rest N974032c5a75441cea3bfad2d337b417e
145 N9bc50042f115409ab736bba9d970609a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Bacterial Infections
147 rdf:type schema:DefinedTerm
148 Na9fa56151cf04b309421ca67eba07583 schema:name Springer Nature - SN SciGraph project
149 rdf:type schema:Organization
150 Nb302cd924fea49b0a2e9094c18b8e6c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Dose-Response Relationship, Drug
152 rdf:type schema:DefinedTerm
153 Nb59ab587d2c747e292cd583f3809445a schema:name pubmed_id
154 schema:value 28399872
155 rdf:type schema:PropertyValue
156 Nbb9588c2fdd441b68b902e22cb44a729 rdf:first sg:person.01022254117.82
157 rdf:rest N927e31f4dd474e92a8fd008455cff0ef
158 Nc452c45ac90142c3915544b4e36ff06a rdf:first sg:person.0676117053.42
159 rdf:rest Nbb9588c2fdd441b68b902e22cb44a729
160 Nc5691f2f525e4acb8520c35047f0b766 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Male
162 rdf:type schema:DefinedTerm
163 Nc82b2579b54e46f4a4e80832bad5d735 rdf:first sg:person.0623735761.04
164 rdf:rest rdf:nil
165 Ncf58b6c6388e4b839aae300325c78878 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Prospective Studies
167 rdf:type schema:DefinedTerm
168 Nd1f31491c33d4540bc3b097530bf22b0 rdf:first sg:person.0743612263.53
169 rdf:rest N18f8bef8b9a445dcb51a9b88561edd6b
170 Nd57852dbbcd549fa8ab514a6c2f7227a schema:name dimensions_id
171 schema:value pub.1084746204
172 rdf:type schema:PropertyValue
173 Nd7cf7de815194ee0a529b6e4cde51e3d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Prothrombin Time
175 rdf:type schema:DefinedTerm
176 Nedfb11e27fe045ff9046ee6f6ad9fb73 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Indicators and Reagents
178 rdf:type schema:DefinedTerm
179 Nef52197ad77141a3be6cdd27f14a7500 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Anticoagulants
181 rdf:type schema:DefinedTerm
182 Nfb775fc9ef2c4cdd8aed4ad9af19adb5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Daptomycin
184 rdf:type schema:DefinedTerm
185 Nfcfeb690913c44b9a79027b1199e3114 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Japan
187 rdf:type schema:DefinedTerm
188 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
189 schema:name Medical and Health Sciences
190 rdf:type schema:DefinedTerm
191 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
192 schema:name Public Health and Health Services
193 rdf:type schema:DefinedTerm
194 sg:grant.5908292 http://pending.schema.org/fundedItem sg:pub.10.1186/s12941-017-0203-3
195 rdf:type schema:MonetaryGrant
196 sg:journal.1031269 schema:issn 1476-0711
197 schema:name Annals of Clinical Microbiology and Antimicrobials
198 schema:publisher Springer Nature
199 rdf:type schema:Periodical
200 sg:person.01022254117.82 schema:affiliation grid-institutes:grid.412708.8
201 schema:familyName Yamamoto
202 schema:givenName Takehito
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022254117.82
204 rdf:type schema:Person
205 sg:person.010343600133.61 schema:affiliation grid-institutes:grid.412708.8
206 schema:familyName Jubishi
207 schema:givenName Daisuke
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010343600133.61
209 rdf:type schema:Person
210 sg:person.012505111435.41 schema:affiliation grid-institutes:grid.412708.8
211 schema:familyName Hashimoto
212 schema:givenName Hideki
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012505111435.41
214 rdf:type schema:Person
215 sg:person.012555337103.96 schema:affiliation grid-institutes:grid.412708.8
216 schema:familyName Suzuki
217 schema:givenName Hiroshi
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012555337103.96
219 rdf:type schema:Person
220 sg:person.0623735761.04 schema:affiliation grid-institutes:grid.412708.8
221 schema:familyName Yotsuyanagi
222 schema:givenName Hiroshi
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623735761.04
224 rdf:type schema:Person
225 sg:person.0670630573.59 schema:affiliation grid-institutes:grid.415016.7
226 schema:familyName Hatakeyama
227 schema:givenName Shuji
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0670630573.59
229 rdf:type schema:Person
230 sg:person.0676117053.42 schema:affiliation grid-institutes:grid.412708.8
231 schema:familyName Kume
232 schema:givenName Yukio
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0676117053.42
234 rdf:type schema:Person
235 sg:person.0743612263.53 schema:affiliation grid-institutes:grid.412708.8
236 schema:familyName Saito
237 schema:givenName Makoto
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0743612263.53
239 rdf:type schema:Person
240 sg:person.07546217533.04 schema:affiliation grid-institutes:grid.412708.8
241 schema:familyName Suzuki
242 schema:givenName Takumitsu
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07546217533.04
244 rdf:type schema:Person
245 sg:person.0765110307.99 schema:affiliation grid-institutes:grid.412708.8
246 schema:familyName Kaneko
247 schema:givenName Makoto
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0765110307.99
249 rdf:type schema:Person
250 sg:pub.10.1186/s12941-016-0130-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045323496
251 https://doi.org/10.1186/s12941-016-0130-8
252 rdf:type schema:CreativeWork
253 grid-institutes:grid.412708.8 schema:alternateName Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
254 Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
255 Department of Pharmacy, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
256 schema:name Department of Clinical Laboratory, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
257 Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
258 Department of Pharmacy, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
259 rdf:type schema:Organization
260 grid-institutes:grid.415016.7 schema:alternateName Division of General Internal Medicine, Division of Infectious Diseases, Jichi Medical University Hospital, 3311-1 Yakushiji, 329-0498, Shimotsuke-shi, Tochigi, Japan
261 schema:name Department of Infectious Diseases, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo-ku, 113-8655, Tokyo, Japan
262 Division of General Internal Medicine, Division of Infectious Diseases, Jichi Medical University Hospital, 3311-1 Yakushiji, 329-0498, Shimotsuke-shi, Tochigi, Japan
263 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...